Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CERO

CERo Therapeutics Holdings Inc

Oct 31 • 03:59PM ET

0.0705

-0.0246 -25.87 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX INO VXRT PGEN CTMX ADVM TFFP APVO

Index	-	P/E	-	EPS (ttm)	-258.19	Insider Own	5.48%	Shs Outstand	1.19M	Perf Week	-96.31%
Market Cap	0.08M	Forward P/E	-	EPS next Y	-2.71	Insider Trans	0.00%	Shs Float	1.14M	Perf Month	-98.69%
Enterprise Value	6.00M	PEG	-	EPS next Q	-1.08	Inst Own	18.61%	Short Float	16.92%	Perf Quarter	-99.08%
Income	-39.13M	P/S	-	EPS this Y	96.81%	Inst Trans	15.42%	Short Ratio	0.09	Perf Half Y	-99.59%
Sales	0.00M	P/B	-	EPS next Y	77.18%	ROA	-178.75%	Short Interest	0.19M	Perf YTD	-99.94%
Book/sh	-8.48	P/C	0.02	EPS next 5Y	81.13%	ROE	-	52W High	895.40 -99.99%	Perf Year	-99.96%
Cash/sh	3.29	P/FCF	-	EPS past 3/5Y	-35.78% -	ROIC	-	52W Low	0.09 -17.06%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	88.69% 32.19%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	68.17%	Oper. Margin	-	ATR (14)	0.41	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.56	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	12.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.56	EPS Q/Q	79.59%	SMA20	-97.34%	Beta	0.34	Target Price	22.50
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-98.49%	Rel Volume	3.58	Prev Close	0.10
Employees	-	LT Debt/Eq	-	Earnings	Sep 03	SMA200	-99.52%	Avg Volume	2.03M	Price	0.07
IPO	Nov 30, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	72.67% -	Trades		Volume	7,271,281	Change	-25.87%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-25	Upgrade	D. Boral Capital	Hold → Buy	$30

Oct-29-25 07:22PM	CERo Therapeutics Announces Receipt of Nasdaq Panel Determination (GlobeNewswire) -94.69%
Oct-21-25 08:15AM	CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML (GlobeNewswire) -16.25%
Oct-15-25 08:30AM	CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 (GlobeNewswire) -8.61%
Oct-13-25 08:30AM	CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML (GlobeNewswire)
Sep-22-25 09:15AM	CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort (GlobeNewswire)
08:15AM	Loading…
Sep-09-25 08:15AM	CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 (GlobeNewswire)
Sep-08-25 08:45AM	CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) -20.95%
Sep-05-25 08:00AM	CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) (GlobeNewswire) -14.57%
Jul-31-25 08:10AM	CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 (GlobeNewswire) +10.86%
Jul-08-25 12:00AM	Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial (Business Wire)
Jun-23-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 (GlobeNewswire) -23.60%
Jun-17-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) (GlobeNewswire) +188.73%
Jun-12-25 09:15AM	Cero Therapeutics announces 1-for-20 reverse stock split (TipRanks) +6.64%
Jun-11-25 09:10AM	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire)
Jun-06-25 08:15AM	CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing (GlobeNewswire) +6.19%
09:20AM	Loading…
Jun-03-25 09:20AM	Cero announces two granted U.S. patents, European patent application allowance (TipRanks)
Jun-02-25 09:05AM	CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236 (GlobeNewswire)
May-30-25 08:15AM	CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations (GlobeNewswire) -13.85%
May-08-25 08:15AM	CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) (GlobeNewswire)
Apr-30-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) -6.11%
Apr-25-25 08:15AM	CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (GlobeNewswire) -19.81%
Apr-24-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +38.85%
Apr-22-25 08:15AM	CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing (GlobeNewswire) +18.70%
Apr-10-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 (GlobeNewswire) -7.89%
Apr-09-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia (GlobeNewswire) +18.58%
Mar-31-25 08:15AM	CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors (GlobeNewswire)
Mar-27-25 08:15AM	CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing (GlobeNewswire) -9.51%
Mar-19-25 08:15AM	CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services (GlobeNewswire)
Mar-13-25 08:15AM	CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting (GlobeNewswire) -29.40%
Mar-06-25 08:15AM	CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays (GlobeNewswire)
08:15AM	Loading…
Mar-05-25 08:15AM	CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14 (GlobeNewswire)
Feb-06-25 08:15AM	CERo Therapeutics Holdings, Inc. Highlights Progress (GlobeNewswire)
Feb-05-25 08:00PM	CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-07-25 08:13AM	Cero Therapeutics to effect 1-for-100 reverse stock split (TipRanks) +23.64%
Jan-06-25 08:00AM	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split (GlobeNewswire) -27.32%
Dec-06-24 09:00AM	CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO (GlobeNewswire) -39.95%
Nov-15-24 08:45AM	CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia (GlobeNewswire) +52.40%
Nov-11-24 08:15AM	CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity (GlobeNewswire) +180.00%
Oct-21-24 09:00AM	CERo Therapeutics, Inc. Provides Corporate Update (GlobeNewswire)
Oct-02-24 09:15AM	CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer (GlobeNewswire) -14.23%
Sep-25-24 09:17AM	CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 (GlobeNewswire) +6.72%
Jul-08-24 08:00AM	CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024 (GlobeNewswire) -18.46%
Jun-13-24 08:15AM	CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236 (GlobeNewswire) -48.86%
Jun-06-24 10:15AM	Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy (ACCESSWIRE) -16.47%
08:00AM	CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236 (GlobeNewswire)
May-15-24 08:00AM	CERo Therapeutics, Inc. Provides Corporate Update for Shareholders (GlobeNewswire)
Apr-30-24 09:00AM	CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes (GlobeNewswire)
Mar-07-24 07:00AM	CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients (Business Wire) +20.78%
Feb-14-24 04:48PM	Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination (Business Wire) -16.24%
Jun-05-23 08:00AM	CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics (Business Wire)

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ATWOOD BRIAN G	Director	Mar 31 '25	Option Exercise	0.00	294,460	29	490,534	Apr 04 07:12 PM
YK Bioventures Opportunities G	10% Owner	Dec 13 '24	Sale	0.06	2,998,908	179,934	13,005,169	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 12 '24	Sale	0.07	1,614,541	113,018	16,004,077	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 11 '24	Sale	0.08	1,343,801	107,504	17,618,618	Dec 13 06:41 PM
YK Bioventures Opportunities G	10% Owner	Dec 06 '24	Sale	0.12	1,236,874	148,425	21,383,909	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 10 '24	Sale	0.09	1,570,947	141,385	18,962,419	Dec 10 08:44 PM
YK Bioventures Opportunities G	10% Owner	Dec 09 '24	Sale	0.11	850,543	93,560	20,533,366	Dec 10 08:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CERO

CERo Therapeutics Holdings Inc

Upgrade your FINVIZ experience